Tags

Type your tag names separated by a space and hit enter

A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients.
J Am Soc Hypertens. 2014 Aug; 8(8):578-92.JA

Abstract

To determine whether telmisartan improves insulin resistance compared with other antihypertensive drugs, we performed a meta-analysis of randomized controlled trials (RCTs) of telmisartan. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through December 2013. Eligible studies were prospective RCTs of telmisartan versus other antihypertensive drugs, enrolling individuals with hypertension and reporting insulin levels and/or homeostasis model assessment-insulin resistance (HOMA-IR) as outcomes. Of 67 potentially relevant articles screened initially, 33 reports of RCTs enrolling a total of 2033 patients with hypertension were identified and included. Pooled analyses of only the eight double-blind-design trials demonstrated statistically significant reductions in percent changes of insulin levels (mean difference, -5.19%; 95% confidence interval, -8.94% to -1.43%; P = .007) and HOMA-IR (-15.34%; -26.39% to -4.28%; P = .007) with telmisartan relative to other antihypertensive drugs. When data from all the 33 trials were pooled, telmisartan was associated with statistically significant reductions in percent changes of insulin levels (-10.92%; -15.60% to -6.23%; P < .00001) and HOMA-IR (-15.89%; -22.01% to -9.78%; P < .00001) relative to other antihypertensive drugs. In conclusion, telmisartan appears to significantly improve insulin resistance compared with other antihypertensive drugs in patients with hypertension.

Authors+Show Affiliations

Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan. Electronic address: kfgth973@ybb.ne.jp.Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.No affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

25151319

Citation

Takagi, Hisato, et al. "A Meta-analysis of Randomized Trials of Telmisartan Versus Active Controls for Insulin Resistance in Hypertensive Patients." Journal of the American Society of Hypertension : JASH, vol. 8, no. 8, 2014, pp. 578-92.
Takagi H, Umemoto T, All-Literature Investigation of Cardiovascular Evidence Group. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. J Am Soc Hypertens. 2014;8(8):578-92.
Takagi, H., & Umemoto, T. (2014). A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. Journal of the American Society of Hypertension : JASH, 8(8), 578-92. https://doi.org/10.1016/j.jash.2014.05.006
Takagi H, Umemoto T, All-Literature Investigation of Cardiovascular Evidence Group. A Meta-analysis of Randomized Trials of Telmisartan Versus Active Controls for Insulin Resistance in Hypertensive Patients. J Am Soc Hypertens. 2014;8(8):578-92. PubMed PMID: 25151319.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. AU - Takagi,Hisato, AU - Umemoto,Takuya, AU - ,, Y1 - 2014/05/15/ PY - 2014/04/16/received PY - 2014/05/08/revised PY - 2014/05/10/accepted PY - 2014/8/25/entrez PY - 2014/8/26/pubmed PY - 2015/5/13/medline KW - Hypertension KW - randomized controlled trial SP - 578 EP - 92 JF - Journal of the American Society of Hypertension : JASH JO - J Am Soc Hypertens VL - 8 IS - 8 N2 - To determine whether telmisartan improves insulin resistance compared with other antihypertensive drugs, we performed a meta-analysis of randomized controlled trials (RCTs) of telmisartan. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through December 2013. Eligible studies were prospective RCTs of telmisartan versus other antihypertensive drugs, enrolling individuals with hypertension and reporting insulin levels and/or homeostasis model assessment-insulin resistance (HOMA-IR) as outcomes. Of 67 potentially relevant articles screened initially, 33 reports of RCTs enrolling a total of 2033 patients with hypertension were identified and included. Pooled analyses of only the eight double-blind-design trials demonstrated statistically significant reductions in percent changes of insulin levels (mean difference, -5.19%; 95% confidence interval, -8.94% to -1.43%; P = .007) and HOMA-IR (-15.34%; -26.39% to -4.28%; P = .007) with telmisartan relative to other antihypertensive drugs. When data from all the 33 trials were pooled, telmisartan was associated with statistically significant reductions in percent changes of insulin levels (-10.92%; -15.60% to -6.23%; P < .00001) and HOMA-IR (-15.89%; -22.01% to -9.78%; P < .00001) relative to other antihypertensive drugs. In conclusion, telmisartan appears to significantly improve insulin resistance compared with other antihypertensive drugs in patients with hypertension. SN - 1878-7436 UR - https://www.unboundmedicine.com/medline/citation/25151319/A_meta_analysis_of_randomized_trials_of_telmisartan_versus_active_controls_for_insulin_resistance_in_hypertensive_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1933-1711(14)00557-9 DB - PRIME DP - Unbound Medicine ER -